Replimune Presents 3-Year Survival and RP2 Phase 1 Safety Data at ASCO
Replimune secured two ASCO oral sessions presenting a three-year overall survival analysis of RP1 plus nivolumab in anti-PD-1 resistant melanoma and safety data from its RP2 phase 1 trial. Four posters will detail intratumoral RP1/RP2 safety and randomized RP2 combination trials in metastatic uveal melanoma, advanced melanoma and liver cancers.
1. ASCO Oral Presentations
Replimune will deliver two oral abstracts at the ASCO Annual Meeting in Chicago, including a three-year landmark overall survival analysis of RP1 plus nivolumab in anti-PD-1 resistant melanoma patients and final safety and efficacy findings from the phase 1 first-in-human RP2 trial in advanced solid tumors.
2. Poster Session Highlights
Four poster presentations will examine intratumoral RP1/RP2 safety across visceral metastases, a randomized phase 2/3 RP2 plus nivolumab versus ipilimumab plus nivolumab study in metastatic uveal melanoma, a phase 3 RP1 plus nivolumab trial in progressed advanced melanoma, and a multicenter RP2 combination study in hepatocellular and biliary tract cancers.
3. Strategic Implications
These data presentations underscore Replimune’s focus on oncolytic immunotherapies RP1 and RP2, highlighting their potential to enhance anti-tumor immunity, inform biomarker-driven development, and support progression toward late-stage trials and regulatory milestones.